Cambridge Antibody Technology was boosted yesterday after saying that preliminary results of a Phase I clinical trial of CAT-354 – its investigational treatment for severe asthma – was well tolerated with no safety concerns identified.
The objective of the trial, which began last September, was to assess the safety, tolerability and pharmacokinetics of CAT-354. It included 34 mild asthmatic patients and the full results will be submitted to an appropriate scientific meeting in due course. Based on these results, CAT is planning to start a clinical pharmacology study in the fourth quarter of 2005.
Patrick Round, vice president of development at CAT, commented: “CAT-354 is an important product candidate for CAT and this trial was the first clinical step in its development as a potential treatment for severe asthma. We are encouraged by these preliminary results and are now moving forward with plans for a second clinical trial.”
